Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

cellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the timing and scope of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... During the conduct of research involving ... principles of good clinical practice (GCP) and human ... Lim, Fellow, Clinical Development at Novartis Pharmaceuticals, will ... the International Conference on Harmonization (ICH) Guideline for ... the conduction of clinical trials ,     Apply ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... NEW YORK, April 3 /PRNewswire-Asia-FirstCall/ -- China Agri-Business, ... agricultural,application products through its operating company in China, ... 31,2008. , Revenue for ... a,decrease of 3.8% as compared to $3,037,414 for ...
... CAMBRIDGE, Mass., April 3 Verenium Corporation (Nasdaq: ... development of high-performance specialty enzymes and next-generation cellulosic ... of Verenium,s demonstration-scale facility in Jennings, Louisiana, and ... with BP, Verenium is now consolidating its research ...
... tiny wires with a diameter as small as ... for devices of the future, both in technology like ... circuits for next generation of electronics. But in order ... must be precisely controlled, and researchers must better understand ...
Cached Biology Technology:China Agri-Business Announces 2008 Operating Results 2China Agri-Business Announces 2008 Operating Results 3China Agri-Business Announces 2008 Operating Results 4China Agri-Business Announces 2008 Operating Results 5Verenium Announces Organizational Changes 2Verenium Announces Organizational Changes 3Researchers peer into nanowires to measure dopant properties 2
(Date:5/23/2013)... HOUSTON (May 23, 2013) A new report ... responsible for helping pupils engage in at least 60 ... school day. , No more than half of American ... hour of vigorous or moderate intensity physical activity daily, ... , "Because children are in school for nearly half ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
(Date:5/22/2013)... Forest Service scientists are part of "Landscapes of Resilience", ... Foundation, will examine how collaborative planning and stewardship of ... , The TKF Foundation announced today that Landscapes of ... funding. In addition to research on the role of ... the 3-year, $585,000 grant will contribute to the creation ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... thousand species (give or take 1.3 million). That is ... the most precise calculation ever offered -- with 6.5 million ... of the total) dwelling in the ocean depths. Announced ... based on an innovative, validated analytical technique that dramatically narrows ...
... physics-based theory could give researchers a deeper understanding of ... polymers. This advance provides a better picture of how ... plastics and other polymeric materials. Kenneth S. Schweizer, ... science and engineering at the University of Illinois, and ...
... An extreme form of pregnancy-related nausea and vomiting known ... of women each year and can lead to hospitalization and ... the only victims. A joint study by ... children whose mothers suffered from HG while carrying them were ...
Cached Biology News:How many species on Earth? 8.7 million 2How many species on Earth? 8.7 million 3How many species on Earth? 8.7 million 4How many species on Earth? 8.7 million 5New theory may shed light on dynamics of large-polymer liquids 2Extreme morning sickness could lead to lifelong emotional, behavioral disorders in kids 2
... is a hairpin primer labeled with ... and non-fluorescent quencher) and a 3 ... is identical to the UniPrimer provided ... (S7901) and is provided at a ...
...
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
... The JASCO Model AS-2055 and AS-2057 ... greater productivity and,the highest possible level of ... to 384 well positions (microplate) for,laboratory automation ... rack for 84 micro-vials or the standard ...
Biology Products: